Galmed Pharmaceuticals acquired Colospan in a $4.5 million million deal as the Israel-based biotech looks to create a gastrointestinal platform targeting a dx sector valued at $6 billion.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
Galmed Pharmaceuticals acquired Colospan in a $4.5 million million deal as the Israel-based biotech looks to create a gastrointestinal platform targeting a dx sector valued at $6 billion.